Q1 Earnings Estimate for Affimed Issued By Leerink Partnrs

Affimed (NASDAQ:AFMD) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Affimed in a note issued to investors on Tuesday, December 17th. Leerink Partnrs analyst D. Graybosch expects that the biopharmaceutical company will post earnings of ($0.59) per share for the quarter. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share.

A number of other research analysts also recently weighed in on the company. Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus cut their price target on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Stock Up 0.8 %

Shares of NASDAQ AFMD opened at $1.19 on Friday. The company’s 50 day simple moving average is $2.92 and its 200 day simple moving average is $4.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. Affimed has a fifty-two week low of $1.14 and a fifty-two week high of $8.95.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. raised its position in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. Intellectus Partners LLC raised its holdings in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. FMR LLC lifted its stake in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Affimed in the third quarter valued at approximately $44,000. Finally, Choreo LLC bought a new stake in shares of Affimed during the second quarter worth $54,000. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.